HI Mariana ... I enjoyed the articles. There is one big clarification on the "Merck and AI Drug Discovery " article: There are two different Merck companies - US and Germany ... the article mix news from both as the same Merck ... I rectification will be appreciate it. Thanks and keep the good work.
The company is known as Merck in the U.S. and Canada. Everywhere else, is known as MSD (is already mentioned in the article). The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. Although they have two names globally, they are one company with one purpose.
If you meant to compile news about Merck US, then you also included articles related to Merck KGaA in Germany. Two different companies. For example the news related BenevolentAi (sep 20 2023) and the one about NucleiAI … these are clearly about Merck KGaA in Germany.
HI Mariana ... I enjoyed the articles. There is one big clarification on the "Merck and AI Drug Discovery " article: There are two different Merck companies - US and Germany ... the article mix news from both as the same Merck ... I rectification will be appreciate it. Thanks and keep the good work.
The company is known as Merck in the U.S. and Canada. Everywhere else, is known as MSD (is already mentioned in the article). The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. Although they have two names globally, they are one company with one purpose.
If you meant to compile news about Merck US, then you also included articles related to Merck KGaA in Germany. Two different companies. For example the news related BenevolentAi (sep 20 2023) and the one about NucleiAI … these are clearly about Merck KGaA in Germany.
The keyword in the title is "Merck": an umbrella term for
1) Merck Research Labs,
2) Merck—known as MSD outside of the U.S. and Canada,
3) Merck KGaA,
4) Merck of Germany,
5) Merck Digital Sciences Studio (MDSS),
6) Merck & Co and
7) Merck Global Health Innovation Fund.
The article is not an historical analysis of the dispute between the two Mercks, but about AI collaborations with references to other sources.